Beyond molecular tumor heterogeneity: protein synthesis takes control

[1]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[2]  O. Larsson,et al.  Cancer as an ecomolecular disease and a neoplastic consortium. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[3]  M. Milik,et al.  Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors. , 2017, Current medicinal chemistry.

[4]  P. A. Thompson,et al.  Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity , 2017 .

[5]  C. Chai,et al.  Eukaryotic translation initiation factor 4E (eIF-4E) expressions are associated with poor prognosis in colorectal adenocarcinoma. , 2017, Pathology, research and practice.

[6]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[7]  P. A. Thompson,et al.  Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade , 2017 .

[8]  N. Demartines,et al.  Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity , 2017, Oxidative medicine and cellular longevity.

[9]  G. Wertheim,et al.  Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma , 2017, American journal of hematology.

[10]  Peng Zhang,et al.  Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy , 2016, Oncotarget.

[11]  L. Xu,et al.  Phosphorylated 4E-BP1 is associated with tumor progression and adverse prognosis in colorectal cancer. , 2017, Neoplasma.

[12]  S. Fan,et al.  Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas , 2017, Journal of Neuro-Oncology.

[13]  T. Rodríguez,et al.  Cell Competition and Its Role in the Regulation of Cell Fitness from Development to Cancer. , 2016, Developmental cell.

[14]  Kyuson Yun,et al.  Addressing intra-tumoral heterogeneity and therapy resistance , 2016, Oncotarget.

[15]  Xuemei Jiang,et al.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma , 2016, Journal of Cancer Research and Clinical Oncology.

[16]  S. Ramón y. Cajal,et al.  peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas , 2016, Cancer medicine.

[17]  M. Gritsenko,et al.  Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation , 2016, Proceedings of the National Academy of Sciences.

[18]  B. Dai,et al.  Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma , 2016, Scientific Reports.

[19]  M. Salto‐Tellez,et al.  Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment , 2016, Scientific Reports.

[20]  Rachel M. Webster.  Combination therapies in oncology , 2016, Nature Reviews Drug Discovery.

[21]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[22]  Eun Hee Lee,et al.  Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer , 2015, Virchows Archiv.

[23]  N. Sonenberg,et al.  Signalling to eIF4E in cancer , 2015, Biochemical Society transactions.

[24]  B. Kholodenko,et al.  The dynamic control of signal transduction networks in cancer cells , 2015, Nature Reviews Cancer.

[25]  B. Jasani,et al.  Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. , 2015, American journal of cancer research.

[26]  C. Teng,et al.  eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer , 2015, Oncotarget.

[27]  M. Martinka,et al.  eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion. , 2015, The Journal of investigative dermatology.

[28]  N. Sonenberg,et al.  Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches , 2015, PloS one.

[29]  Eun Hee Lee,et al.  Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer. , 2015, Pathology, research and practice.

[30]  H. Miyake,et al.  Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder. , 2015, Urologic oncology.

[31]  N. Sonenberg,et al.  Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.

[32]  Eun Hee Lee,et al.  Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. , 2015, International journal of clinical and experimental pathology.

[33]  Simone Severini,et al.  Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer , 2015, PLoS Comput. Biol..

[34]  N. Sonenberg,et al.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. , 2015, Cancer research.

[35]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[36]  J. Dufour,et al.  Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[37]  James H. Doroshow,et al.  Translational research in oncology—10 years of progress and future prospects , 2014, Nature Reviews Clinical Oncology.

[38]  Zhonghu Bai,et al.  Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling , 2014, Scientific Reports.

[39]  Dong Yan,et al.  Clinical Significance of mTOR and eIF4E Expression in Invasive Ductal Carcinoma , 2014, Tumori.

[40]  S. Y. Cajal,et al.  The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets , 2014, Clinical and Translational Oncology.

[41]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[42]  E. Bellolio,et al.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance , 2014, Virchows Archiv.

[43]  Wei Wang,et al.  Expression of eukaryotic initiation factor 4 E in hypopharyngeal carcinoma , 2014, The Journal of international medical research.

[44]  Sunita K. C. Basnet,et al.  Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation , 2014, ChemMedChem.

[45]  Lei Lu,et al.  Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma , 2014, Medical Oncology.

[46]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[47]  S. Fan,et al.  Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma , 2014, PloS one.

[48]  P. Purushottamachar,et al.  First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines , 2014, Oncotarget.

[49]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[50]  D. Sgroi,et al.  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials , 2013, Breast Cancer Research.

[51]  Jeffrey Hill,et al.  Rational Design of Resorcylic Acid Lactone Analogues as Covalent MNK1/2 Kinase Inhibitors by Tuning the Reactivity of an Enamide Michael Acceptor , 2013, ChemMedChem.

[52]  Sofia Khan,et al.  Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment , 2013, Breast Cancer Research and Treatment.

[53]  Guanzhen Yu,et al.  Overexpression of p-4ebp1 in Chinese gastric cancer patients and its correlation with prognosis. , 2013, Hepato-gastroenterology.

[54]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[55]  J. Pelletier,et al.  eIF4F suppression in breast cancer affects maintenance and progression , 2013, Oncogene.

[56]  K. Harada,et al.  Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors , 2013, Medical Oncology.

[57]  E. Campo,et al.  Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.

[58]  P. Korkolopoulou,et al.  Phosphorylated 4E‐binding protein 1 (p‐4E‐BP1): a novel prognostic marker in human astrocytomas , 2012, Histopathology.

[59]  G. Wagner,et al.  Tumor suppression by small molecule inhibitors of translation initiation , 2012, Oncotarget.

[60]  N. Sonenberg,et al.  Translational homeostasis via the mRNA cap-binding protein, eIF4E. , 2012, Molecular cell.

[61]  J. Baselga,et al.  Molecular prescreening to select patient population in early clinical trials , 2012, Nature Reviews Clinical Oncology.

[62]  N. Normanno,et al.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches , 2012, Expert opinion on therapeutic targets.

[63]  High phosphorylated 4E‐binding protein 1 expression after chemoradiotherapy is a predictor for locoregional recurrence and worse survival in esophageal squamous cell carcinoma patients , 2012, Journal of surgical oncology.

[64]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[65]  S. Ramón y. Cajal,et al.  The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. , 2011, International journal of oncology.

[66]  M. Fishman,et al.  A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[67]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[68]  S. Vajda,et al.  Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication , 2011, Journal of Virology.

[69]  H. Sørensen,et al.  Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007) , 2011, Breast Cancer Research and Treatment.

[70]  Tomoyuki Tsumuraya,et al.  Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. , 2011, Biochemical pharmacology.

[71]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[72]  Nahum Sonenberg,et al.  Cap and cap‐binding proteins in the control of gene expression , 2011, Wiley interdisciplinary reviews. RNA.

[73]  N. Sonenberg,et al.  Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. , 2011, Cancer research.

[74]  C. Tseng,et al.  High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma , 2011, Virchows Archiv.

[75]  Kenji Eguchi,et al.  Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. , 2010, Lung cancer.

[76]  M. Bushell,et al.  Translational regulation of gene expression during conditions of cell stress. , 2010, Molecular cell.

[77]  Lani F. Wu,et al.  Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities , 2010, Molecular systems biology.

[78]  S. Formenti,et al.  Translational control in cancer , 2010, Nature Reviews Cancer.

[79]  J. Salk.  Clonal evolution in cancer , 2010 .

[80]  S. Ramón y. Cajal,et al.  Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[81]  Long-Bang Chen,et al.  Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. , 2009, Lung cancer.

[82]  S. Ramón y. Cajal,et al.  Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. , 2009, Human pathology.

[83]  C. Wagner,et al.  Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. , 2009, ACS chemical biology.

[84]  Zhihong Chen,et al.  Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A , 2009, Molecular Cancer Therapeutics.

[85]  R. Cencic,et al.  Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol , 2009, PloS one.

[86]  G. Mills,et al.  Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma , 2009, Clinical Cancer Research.

[87]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[88]  J. Aguirre-Ghiso,et al.  Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. , 2009, Cancer research.

[89]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[90]  W. Weichert,et al.  Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro , 2009, Journal of Cancer Research and Clinical Oncology.

[91]  S. Lowe,et al.  Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. , 2008, The Journal of clinical investigation.

[92]  C. Proud,et al.  The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). , 2008, Frontiers in bioscience : a journal and virtual library.

[93]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Graff,et al.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.

[95]  J. Baselga,et al.  4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. , 2007, Cancer research.

[96]  A. Degterev,et al.  Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G , 2007, Cell.

[97]  J. Baselga,et al.  4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis , 2007, Clinical Cancer Research.

[98]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[99]  J. Baselga,et al.  Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer , 2006, Cancer.

[100]  Michele Pagano,et al.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. , 2006, Science.

[101]  K. Borden,et al.  Phosphorylation of the Eukaryotic Translation Initiation Factor eIF4E Contributes to Its Transformation and mRNA Transport Activities , 2004, Cancer Research.

[102]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[103]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[104]  N. Sonenberg,et al.  The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation , 2003, Molecular and Cellular Biology.

[105]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[106]  Benjamin D. L. Li,et al.  Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome , 2002, Annals of surgery.

[107]  G. Scheper,et al.  Phosphorylation of Eukaryotic Initiation Factor 4E Markedly Reduces Its Affinity for Capped mRNA* , 2002, The Journal of Biological Chemistry.

[108]  H. Gram,et al.  Negative Regulation of Protein Translation by Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 , 2001, Molecular and Cellular Biology.

[109]  N. Sonenberg,et al.  The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. , 2001, RNA.

[110]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[111]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[112]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[114]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[115]  Jonathan A. Cooper,et al.  Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.

[116]  Tony Hunter,et al.  MNK1, a new MAP kinase‐activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates , 1997, The EMBO journal.

[117]  A. Gingras,et al.  4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[118]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[119]  A. Gingras,et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.

[120]  N. Sonenberg,et al.  mRNAs containing extensive secondary structure in their 5′ non‐coding region translate efficiently in cells overexpressing initiation factor eIF‐4E. , 1992, The EMBO journal.

[121]  A. De Benedetti,et al.  Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F , 1991, Molecular and cellular biology.